1. The E3 Ubiquitin Ligase HOIP inhibits Cancer Cell Apoptosis via modulating PTEN stability
- Author
-
Shuxiao Dong, Xin Li, Shu Zhuo, Jianhui Gao, Huijie Yang, Yinlu Ding, Wenrong Xu, Jian Zhu, Zhiguo Niu, Hui Qian, Qingsong Huang, and Ting Zhuang
- Subjects
Cisplatin ,PTEN ,Cell cycle checkpoint ,biology ,HOIP ,Ubiquitin ,business.industry ,Cancer ,Apoptosis ,medicine.disease ,Ubiquitin ligase ,Oncology ,Cancer cell ,biology.protein ,Cancer research ,Gene silencing ,Medicine ,business ,Research Paper ,medicine.drug - Abstract
Chemotherapy is widely used in a variety of solid tumors, such as lung cancer, gastric cancer and breast cancer. The genotoxic drugs, such as cisplatin, suppress cancer progression either by inhibition cell proliferation or facilitating apoptosis. However, the chemotherapy resistance remains an urgent challenge in cancer therapy, especially in advanced stages. Several studies showed that the activation of pro-survival pathways, such as PI3K-AKT, participated in mediating chemotherapy resistance. The insights into the molecular mechanisms for underlying chemotherapy resistance are of great importance to improve cancer patient survival in advanced stages. The HOIP protein belongs to the RING family E3 ubiquitin ligases and modulates several atypical ubiquitination processes in cellular signaling. Previous studies showed that HOIP might be an important effector in modulating cancer cell death under genotoxic drugs. Here, we report that HOIP associates with PTEN and facilitates PTEN degradation in cancer cells. Depletion of HOIP causes cell cycle arrest and apoptosis, which effects could be rescued by PTEN silencing. Besides, the survival data from public available database show that HOIP expression correlates with poor survival in several types of chemotherapy-treated cancer patients. In conclusion, our study establishes a novel mechanism by which HOIP modulates PTEN stability and facilitates chemotherapy resistance in malignancies.
- Published
- 2021